Mohareb A. M. auteur aut IRD Larmarange Joseph auteur aut IRD Kim A. Y. auteur aut IRD Coffie P. A. auteur aut IRD Kouame M. G. auteur aut IRD Boyd A. auteur aut IRD Freedberg K. A. auteur aut IRD Hyle E. P. auteur aut IRD text journalArticle eng text/pdf born digital access Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation. specialized MONDE 050 052 9 8 E585-E594 2022 2352-3018 https://www.documentation.ird.fr/hor/fdi:010086363 10.1016/s2352-3018(22)00123-0 2352-3018 [F B010086363] https://www.documentation.ird.fr/hor/fdi:010086363 https://www.documentation.ird.fr/intranet/publi/2022-11/010086363.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2022-11-09 2025-02-24 fdi:010086363 fre